GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

GE HealthCare Technologies Inc.

In a report released today, Rick Wise from Stifel Nicolaus maintained a Buy rating on GE Healthcare Technologies Inc, with a price target of $80.00...

Stifel Nicolaus Keeps Their Buy Rating on GE Healthcare Technologies Inc (GEHC)

Oppenheimer analyst Suraj Kalia maintained a Buy rating on GE Healthcare Technologies Inc today and set a price target of $85.00. According to TipR...

GE Healthcare Technologies Inc (GEHC) Receives a Buy from Oppenheimer

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Edwards Lifesciences (EW) and GE Healthcare Technolo...

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW) and GE Healthcare Technologies Inc (GEHC)

Stocks ended the week lower as weakness in technology shares and disappointing corporate outlooks weighed on the major U.S. indexes. The Dow Jones ...

The Week That Was, The Week Ahead: Macro and Markets, July 19

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on GE Healthcare Technologies Inc yesterday and set a price target of $80.00. Singh...

RBC Capital Keeps Their Buy Rating on GE Healthcare Technologies Inc (GEHC)

Analysts are intrested in these 5 stocks: ( ($GEHC) ), ( ($AMD) ), ( ($TWLO) ), ( ($PEP) ) and ( ($TOL) ). Here is a breakdown of their recent


GEHC, AMD, TWLO, PEP, TOL Trending With Analysts

Ge Healthcare Technologies Inc. ($GEHC) announced an update on their ongoing clinical study. The study titled “Evaluate Functionality and Use of th...

GE Healthcare’s NMT EasyFit Trial Signals Next Step in Smart Surgical Monitoring

Jefferies analyst Matthew Taylor maintained a Buy rating on GE Healthcare Technologies Inc today and set a price target of $90.00. According to Tip...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GEHC	$62.61	+2.44%	1.13M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GEHC	$62.61	+2.4%	1.13M
3
4
5
6

GEHC

GEHC

Get GE HealthCare Technologies Inc. Data in Excel

Get GE HealthCare Technologies Inc. Data in Excel